Regulus Therapeutics Inc.

1.74
-0.01 (-0.57%)
At close: Apr 01, 2025, 3:59 PM
1.73
-0.57%
After-hours: Apr 01, 2025, 05:27 PM EDT
-0.57%
Bid 1.73
Market Cap 115.26M
Revenue (ttm) n/a
Net Income (ttm) -46.88M
EPS (ttm) -0.83
PE Ratio (ttm) -2.1
Forward PE -0.71
Analyst Buy
Ask 1.78
Volume 2,458,219
Avg. Volume (20D) 1,079,156
Open 1.71
Previous Close 1.75
Day's Range 1.67 - 2.05
52-Week Range 0.83 - 2.90
Beta 1.41

About RGLS

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 9, 2012
Employees 34
Stock Exchange NASDAQ
Ticker Symbol RGLS
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for RGLS stock is "Buy." The 12-month stock price forecast is $7.5, which is an increase of 331.03% from the latest price.

Stock Forecasts
5 days ago
+16.28%
Regulus Therapeutics shares are trading higher aft... Unlock content with Pro Subscription
9 months ago
-18.33%
Regulus Therapeutics shares are trading lower after the company announced results in the Phase 1b Study for ADPKD treatment. The stock initially traded higher, but it has since reversed.